Pfizer vaccine is 90% effective among teens, study finds

Pfizer vaccine is 90% effective among teens, study finds

 Pfizer's U.S. coronavirus vaccine is 90% effective among adolescents between the ages of 12 and 18. Including against the "Delta" strain.

 

This is reported by The Times of Israel.

 

According to a study by the Israeli company Clalit, Harvard University and Boston Children's Hospital, based on an analysis of data from nearly 200,000 adolescents, those who received the vaccine were 90 percent less likely to contract the coronavirus.

 

The study was conducted at a time when the Delta variant was the dominant strain of coronavirus in Israel. It also led the researchers to conclude that the vaccine is just as effective against mutations as it was against earlier versions.

 

"Our results show that the BNT162b2 mRNA vaccine was highly effective in the first few weeks after vaccination against both infection and symptomatic COVID-19 with the 'Delta' variant among adolescents aged 12 to 18 years," the study said.

 

According to the analysis, teens vaccinated between June 8 and September 14 were 59% less likely to contract the coronavirus than teens in the unvaccinated control group two weeks after the first dose and 57% less likely to exhibit COVID-19 symptoms. One week after the second dose, these numbers rose to 90% and 93%, respectively.

 





 Pfizer's U.S. coronavirus vaccine is 90% effective among adolescents between the ages of 12 and 18. Including against the "Delta" strain.

 

This is reported by The Times of Israel.

 

According to a study by the Israeli company Clalit, Harvard University and Boston Children's Hospital, based on an analysis of data from nearly 200,000 adolescents, those who received the vaccine were 90 percent less likely to contract the coronavirus.

 

The study was conducted at a time when the Delta variant was the dominant strain of coronavirus in Israel. It also led the researchers to conclude that the vaccine is just as effective against mutations as it was against earlier versions.

 

"Our results show that the BNT162b2 mRNA vaccine was highly effective in the first few weeks after vaccination against both infection and symptomatic COVID-19 with the 'Delta' variant among adolescents aged 12 to 18 years," the study said.

 

According to the analysis, teens vaccinated between June 8 and September 14 were 59% less likely to contract the coronavirus than teens in the unvaccinated control group two weeks after the first dose and 57% less likely to exhibit COVID-19 symptoms. One week after the second dose, these numbers rose to 90% and 93%, respectively.